Literature DB >> 7498327

Norepinephrine loss exacerbates methamphetamine-induced striatal dopamine depletion in mice.

F Fornai1, L Bassi, M T Torracca, V Scalori, G U Corsini.   

Abstract

Evidence is accumulating that norepinephrine depletion enhances the neurotoxic effect of the parkinsonism inducing neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). In this study we investigated whether norepinephrine loss potentiates methamphetamine-induced striatal dopamine depletion. Injection of C57BL/6N mice with methamphetamine (2 x 5 mg/kg i.p., at 2-h intervals) produced only a partial (50%) striatal dopamine depletion 7 days after drug administration. Pretreatment with the selective noradrenergic neurotoxin N-(-2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4; 50 mg/kg i.p.) enhanced methamphetamine-induced striatal dopamine depletion by 86%, without decreasing striatal dopamine levels when injected alone. Our results extend previous findings obtained with the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine in DSP-4-pretreated mice.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7498327     DOI: 10.1016/0014-2999(95)00313-a

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  26 in total

1.  The role of endogenous serotonin in methamphetamine-induced neurotoxicity to dopamine nerve endings of the striatum.

Authors:  David M Thomas; Mariana Angoa Pérez; Dina M Francescutti-Verbeem; Mrudang M Shah; Donald M Kuhn
Journal:  J Neurochem       Date:  2010-09-06       Impact factor: 5.372

2.  Exendin-4 reverts behavioural and neurochemical dysfunction in a pre-motor rodent model of Parkinson's disease with noradrenergic deficit.

Authors:  N Rampersaud; A Harkavyi; G Giordano; R Lever; J Whitton; Ps Whitton
Journal:  Br J Pharmacol       Date:  2012-12       Impact factor: 8.739

3.  Effect of locus coeruleus denervation on levodopa-induced motor fluctuations in hemiparkinsonian rats.

Authors:  C Marin; E Aguilar; M Bonastre
Journal:  J Neural Transm (Vienna)       Date:  2008-06-05       Impact factor: 3.575

4.  Reduced noradrenergic innervation of ventral midbrain dopaminergic cell groups and the subthalamic nucleus in MPTP-treated parkinsonian monkeys.

Authors:  Gunasingh Jeyaraj Masilamoni; Olivia Groover; Yoland Smith
Journal:  Neurobiol Dis       Date:  2016-12-30       Impact factor: 5.996

5.  Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys.

Authors:  Gunasingh J Masilamoni; James W Bogenpohl; David Alagille; Kristen Delevich; Gilles Tamagnan; John R Votaw; Thomas Wichmann; Yoland Smith
Journal:  Brain       Date:  2011-07       Impact factor: 13.501

6.  Norepinephrine upregulates the expression of tyrosine hydroxylase and protects dopaminegic neurons against 6-hydrodopamine toxicity.

Authors:  Meng-Yang Zhu; Muhammad U Raza; Yanqiang Zhan; Yan Fan
Journal:  Neurochem Int       Date:  2019-09-17       Impact factor: 3.921

Review 7.  Noradrenergic Modulation on Dopaminergic Neurons.

Authors:  Meng-Yang Zhu
Journal:  Neurotox Res       Date:  2018-03-23       Impact factor: 3.911

Review 8.  Nucleus accumbens invulnerability to methamphetamine neurotoxicity.

Authors:  Donald M Kuhn; Mariana Angoa-Pérez; David M Thomas
Journal:  ILAR J       Date:  2011

Review 9.  Locus Coeruleus Modulates Neuroinflammation in Parkinsonism and Dementia.

Authors:  Filippo Sean Giorgi; Francesca Biagioni; Alessandro Galgani; Nicola Pavese; Gloria Lazzeri; Francesco Fornai
Journal:  Int J Mol Sci       Date:  2020-11-16       Impact factor: 5.923

10.  The effect of the alpha2-adrenoreceptor antagonist idazoxan against 6-hydroxydopamine-induced Parkinsonism in rats: multiple facets of action?

Authors:  J Srinivasan; Werner J Schmidt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-04-29       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.